Search Results
Results found for "Stefan Aebi"
- AELIS PHARMA launches their IPO for €25 million
February 2022 "We are proud to announce the success of our IPO! Thank you to our shareholders, both historical and new, for their trust. The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain diseases! #IPO #biotech #innovation #traitements #addiction #cannabis #Trisomie21 #Downsyndrome" Read more at the source #DrGPCR #GPCR #IndustryNews
- Third Rock pushes newest fund over $1B line as it marks 15 years in venture capital
June 2022 "June 15, 2022 06:30 AM EDT - In 2016, Abbie Celniker was promoted to partner at Third Rock
- 📰 GPCR Weekly News, April 1 to 7, 2024
Neurosterix launches with $63M to Advance Allosteric Modulator Therapeutics for Neurological Disorders Aelis
- 📰 GPCR Weekly News, December 4 to 10, 2023
gene therapies for sickle cell disease, including first that uses CRISPR Pier Vincenzo Piazza, CEO of AELIS
- 📰 GPCR Weekly News, September 25 to October 1, 2023
Exscientia plc in deal worth up to $674M 2023 Half-Year Financial Results and Exciting Developments at Aelis
- 📰 GPCR Weekly News, January 8 to 14, 2024
presenting at the OBIO 2024 Investment Summit X-rays to AlphaFold: the future structure of drug discovery Aelis
- 📰 GPCR Weekly News, April 15 to 21, 2024
Industry News Addex Therapeutics Reports Full Year 2023 Financial Results And Provides Corporate Update Aelis
- 📰 GPCR Weekly News, February 12 to 18, 2024
Cellular Communication Bowes Biomedical Investigator Takes Aim at Cracking Cellular Communication Code Aelis
- ⛵Sailing the GPCR Seas: Your Weekly Research Voyage! ⦿ Nov 11 - 17, 2024
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Aelis
- Hop in the Time Machine with GPCR: Unraveling the Future of Research! ⦿ Nov 24 - Dec 1, 2024
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau INAUGURATION OF AELIS
